Medical Blogs

April 16, 2007

Warner Receives Patent Challenge On Oral Contraceptive

U.K. pharmaceutical company Warner Chilcott on Friday said Watson Pharmaceuticals has issued a patent challenge to the company for its oral contraceptive Loestrin 24 FE, the AP/MSNBC.com reports. According to the AP/MSNBC.com, Warner released Loestrin 24 FE in April and holds a patent that does not expire until 2014. Watson has given Warner notice that it is filing an application to make a generic version of Loestrin, which means that Watson is claiming either that it is not infringing on Warner's patent by producing a generic version of the drug or that the patent is invalid, the AP/MSNBC.com reports. Warner has 45 days to file patent litigation (AP/MSNBC.com, 6/23).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

No comments: